» Articles » PMID: 21091434

Substance P Immunoreactive Nerve Fibres Are Related to Gastric Cancer Differentiation Status and Could Promote Proliferation and Migration of Gastric Cancer Cells

Overview
Journal Cell Biol Int
Specialty Cell Biology
Date 2010 Nov 25
PMID 21091434
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Tachykinins such as SP (substance P) may be involved in the progression of gastric adenocarcinoma through binding to NK-1 receptor. However, the existence and relationship between SP and gastric cancer progression and differentiation remained unknown. We have studied the NK-1 receptor in human gastric cancer tissue and MKN45 cell line and found SP-containing nerve fibres in human gastric cancer and found that the amounts of SP-positive nerves were related to gastric cancer differentiation. SP could promote proliferation, adhesion, migration and invasion of MKN45 cells in vitro. In addition, the intracellular calcium level of MKN45 cells was elevated after SP stimulation, and administration of CRACs (calcium release-activated calcium channels) inhibitor SKF-96365 could partially abolish these effects induced by SP. These results demonstrated that NK-1 receptor and SP-containing nerves existed in human gastric cancer; SP positive nerves may play an important role in human gastric cancer progression, and calcium is critically significant among SP-induced biological effects.

Citing Articles

From pain to tumor immunity: influence of peripheral sensory neurons in cancer.

Mardelle U, Bretaud N, Daher C, Feuillet V Front Immunol. 2024; 15:1335387.

PMID: 38433844 PMC: 10905387. DOI: 10.3389/fimmu.2024.1335387.


The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.

Covenas R, Rodriguez F, Robinson P, Munoz M Int J Mol Sci. 2023; 24(21).

PMID: 37958914 PMC: 10650658. DOI: 10.3390/ijms242115936.


The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.

Martin-Garcia D, Tellez T, Redondo M, Garcia-Aranda M Curr Med Chem. 2023; 31(39):6487-6509.

PMID: 37861026 DOI: 10.2174/0109298673261625230924114406.


Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.

Isorna I, Gonzalez-Moles M, Munoz M, Esteban F J Clin Med. 2023; 12(19).

PMID: 37835053 PMC: 10573850. DOI: 10.3390/jcm12196409.


Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.

Cao X, Yang Y, Zhou W, Wang Y, Wang X, Ge X BMC Cancer. 2023; 23(1):471.

PMID: 37221457 PMC: 10204192. DOI: 10.1186/s12885-023-10954-8.